Interim Report Archives - Page 3 of 3

Xspray Pharma publishes Interim report Q4, January – December 2019

PRESS RELEASE February 28, 2020 “One important milestone was reached in June when our production facility in Italy was completed and was able to do a test run. We have now proven that our technology is possible to scale up – and we are the first in the world to manufacture amorphous material in the […]

Xspray Pharma publishes Interim Report Q3, January – September 2019

November 14, 2019 ”It is with a high pace, dedication and broad expertise that Xspray's team continued to drive the development of our furthest progressed product candidate, HyNap-Dasa, towards our first ANDA application. HyNap-Dasa is an amorphous version of Sprycel® (dasatinib). The target of submitting an application to the US FDA during the summer of […]

Xspray Pharma publishes Interim Report Q2, January – June 2019

August 29, 2019 ”We have previously shown that it is possible to manufacture small pilot quantities of amorphous material for clinical studies but now we have shown that the process works at commercial scale. We have ”cracked the code”, so to speak, and have taken a great step toward a finished product.” Per Andersson, CEO […]

Xspray Pharma publishes Interim Report Q1, January-March 2019

May 16, 2019 ”Over the past year, we’ve tripled the number of employees and I’m very pleased to see that our entire team is performing high quality work with great commitment. Xspray is today a company well-equipped to take a drug all the way to a finished product.” Per Andersson, CEO Xspray Pharma AB (publ) […]

Xspray Pharma publishes its Year-end Report, January – December 2018

”Following determined efforts, we demonstrated performance in 2018 that has brought us significantly closer to a market launch of HyNap-Dasa and have thus increased Xspray’s possibilities of building shareholder value.” Per Andersson, CEO Xspray Pharma AB (publ) Fourth quarter, October – December 2018, parent company Amounts in brackets refer to the corresponding period for the […]